An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

BMC Clinical Pharmacology

Owen I Corrigan¹  Maria B Donnelly²  Caitriona M Gowing³  Eoin Casey²  Deirdre M D’Arcy¹ 

[1] School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland;Intensive Care Medicine, Tallaght Hospital, Dublin 24, Ireland;Pharmacy Department, Tallaght Hospital, Dublin 24, Ireland

关键词: Haemodiafiltration;    Pharmacokinetics;    Amikacin;   

Others  :  860714
DOI  :  10.1186/2050-6511-13-14

 received in 2012-05-14, accepted in 2012-10-16,  发布年份 2012

【 摘 要 】

Background

The objectives of the current study were to determine amikacin pharmacokinetics in patients undergoing treatment with continuous venovenous haemodiafiltration (CVVHDF) in an Intensive Care Unit (ICU), and to determine whether peak and trough concentration data could be used to predict pharmacokinetic parameters. An open prospective study was undertaken, comprising five critically ill patients with sepsis requiring CVVHDF.

Methods

Peak and trough plasma concentrations and multiple serum levels in a dosage interval were measured and the latter fitted to both a one- and two-compartment model. Blood and ultrafiltrate samples were collected and assayed for amikacin to calculate the pharmacokinetic parameters; total body clearance (TBC), elimination rate constant (k) and volume of distribution (V_d). The concentration of amikacin in ultrafiltrate was used to determine the clearance via CVVHDF. CVVHDF was performed at prescribed dialysate rates of 1-2l h^-1 and ultrafiltration rate of 2l h^-1. Blood was pumped at 200ml/min using a Gambro blood pump and Hospal AN69HF haemofilter. Amikacin dosing was according to routine clinical practice in the Intensive Care Unit.

Results

The multi serum level study indicated that the one compartment model was adequate to characterize the pharmacokinetics in these patients suggesting that peak and trough plasma level data may be used to estimate individual patient pharmacokinetic parameters and to optimise individual patient dosing during treatment with CVVHDF. CVVHDF resulted in an amikacin k of 0.109+/−0.025 h, t_1/2 of 6.74 +/− 1.69h, TBC of 3.39+/−0.817 h^-1, and V_d of 31.4 +/− 3.27. The mean clearance due to CVVHDF of 2.86 l h^-1 is similar to the creatinine clearance of 2.74 +/−0.4 lh^-1. Amikacin was significantly cleared by CVVHDF, and its half life in patients on CVVHDF was approximately 2–3 times that reported in subjects without renal impairment and not undergoing haemodiafiltration for any reason.

Conclusions

CVVHDF contributes significantly to total clearance of amikacin. The use of pharmacokinetic parameter estimates obtained from two steady state serum-drug concentrations (peak and trough) can be used to guide individualised dosing of critically ill patients treated with CVVHDF. This is considered a useful strategy in this patient cohort, particularly in avoiding the risk of underdosing.

【 授权许可】

   
2012 D'Arcy et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Leone M, Martin C: Antibiotics in the ICU. In 25 years of progress and innovation in intensive care medicine. Edited by Kuhlen R, Moreno R, Ranierie M, Rhodes A. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft; 2007.
• [2]Kelly CP, LaMont T: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the basics). http://www.uptodate.com Accessed 20/04/2012 webcite
• [3]Bristol-Myers Squibb HL: Amikacin Injection 100mg/2ml Summary of Product Characteristics. Dublin: Irish Pharmaceutical Healthcare Association - medicines information online; 2012.
• [4]Winters M: Basic Clinical Pharmacokinetics. 5th edition. New York: Lippincott Williams and Wilkins; 2010.
• [5]Moore R, Smith C, Lietman P: Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984, 77:657-662.
• [6]Moore R, Lietman P, Smith C: Clinical Response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155(1):93-99.
• [7]Roberts J, Kruger P, Paterson D, Lipman J: Antibiotic resistance- What's dosing got to do with it? Crit Care Med 2008, 36(8):2433-2440.
• [8]Barletta J, Johnson S, Nix D, Nix L, Erstad B: Population pharmacokinetics in critically ill trauma patients on once-daily regimens. J Trauma 2000, 49(5):869-872.
• [9]Zaske D, Strate R, Kohls P: Amikacin pharmacokinetics: wide interpatient variation in 98 patients. J Clin Pharmacol 1991, 31(2):158-163.
• [10]Lugo G, Castaneda-Hernandez G: Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997, 255:806-811.
• [11]Udy A, Roberts J, Lipman J: Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011, 7(9):539-543.
• [12]Robert R, Rochard E, Malin F, Bouquet S: Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 1991, 19(4):588-589.
• [13]Armendariz E, Chelluri L, Ptachcinski R: Pharmacokinetics of amikacin during continuous venovenous hemofiltration. Crit Care Med 1990, 18(6):675-676.
• [14]Akers K, Cota J, Frei C, Chung K, Mende K, Murray C: Once-daily amikacin dosing in burns patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 2011, 55(10):4639-4642.
• [15]Pea F, Pierluigi V, Pavan F, Furlanut M: Pharmacokinetic considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy. Clin Pharmacokinet 2007, 46(12):997-1038.
• [16]Moon S-Y, Oh K-H, Oh Y, Curie A, Joo K, Kim Y, Han J, Kim S, Lee J, Kim J-R, et al.: Removal of amikacin in patients undergoing continuous veno-venous hemodiafiltration. The Korean J Nephrology 2006, 25(4):595-601.
• [17]Taccone FS, de Backer D, Laterre P-F, Spapen H, Dugernier T, Delattre I, Wallemacq P, Vincent J-L, Jacobs F: Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011, 37(6):531-535.
• [18]Kinowski J, Coussaye JD, Bressole F, Fabre D, Saissi G, Bouvet O, Galtier M, Eledjam J: Muliple-dose pharmacokinetics of amikacin and ceftaizidime in critically ill patients with septic multiple-organ failure during intermittent haemofiltration. Antimicrob Agents Chemother 1993, 37(3):464-473.
• [19]Layeux B, Taccone F, Fagnoul D, Vincent J-L, Jacobs F: Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54:4939-4941.
• [20]Jelliffe R, Jelliffe S: A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex and weight. Math Biosci 1972, 14(1–2):17-24.
• [21]Bressolle F, Gouby A, Martinez J-M, Joubert P, Saissi G, Guillaud R, Goment R: Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 1996, 40(7):1682-1689.
• [22]Marik P, Lipman J, Kobilski S, Scribante J: A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991, 28:753-764.
• [23]Gabrielsson J, Weiner D: Pharmacokinetic and pharmacodynamic data analysis:concepts and applications. 4th edition. Stockholm: Swedish Pharmaceutical Press; 2000.
• [24]Sawchuk R, Zaske D: Pharmacokinetics of dosage regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmackinet Biopharm 1976, 4(2):183-195.
• [25]Ronchera-Oms C, Tormo C, Ordovas J, Abad J, Jimenez N: Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995, 20(5):253-258.
• [26]Heintz B, Matzke G, Dager W: Antimicrobial dosing concepts and reccomendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009, 29(5):662-577.